Could a common heart pill slow Parkinson's? small trial aims to find out

NCT ID NCT04218968

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether carvedilol, a drug usually used for heart conditions, can slow the loss of dopamine transporters in the brain and delay Parkinson's symptoms. It follows 15 people with REM sleep behavior disorder and other early Parkinson's risk factors over three years. Researchers will use brain scans and clinical checks to see if the drug reduces the rate of decline.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Carvedilol (a heart medication that blocks adrenergic signals)
What this could lead to
If it works, this could point toward a way to slow Parkinson's disease progression in people with early warning signs.
What could go wrong
This is a very small, early-phase study with only 15 participants. It may not show a clear benefit, and carvedilol is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRE-MOTOR PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Michele L Lima Gregorio

    Los Angeles, California, 90046, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.